Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02620748 · ClinicalTrials.gov registry record · Phase 1

Use of Intravenous Tranexamic Acid During Myomectomy

A Phase 1 study of Fibroids and Hemorrhage/Blood Loss During Myomectomies, sponsored by George Washington University.

Completed
Registry status
Phase 1
Development phase
60
Enrollment target
1
Study location

NCT02620748 is a Phase 1 study of Fibroids and Hemorrhage/Blood Loss During Myomectomies that has completed, run by George Washington University. The registered enrollment target is 60 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02620748, a Phase 1 study of Fibroids and Hemorrhage/Blood Loss During Myomectomies, has completed, sponsored by George Washington University.

COMPLETED
Registry status
Phase 1
Development phase
60 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine the effect of the early administration of intravenous (IV) Tranexamic acid (TA) on perioperative bleeding (as defined by measured intraoperative estimated blood loss (EBL), change in pre and post-operative hemoglobin (Hb), and frequency of blood transfusions) in women undergoing a myomectomy.

Interventions

  • DRUG Tranexamic Acid
  • OTHER Saline Solution

Study Locations (1)

District of Columbia

  • Medical Faculty Associates - Washington D.C.

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2015-03
Est. Completion 2018-02-22
Phase Phase 1

Sponsor

George Washington University

133 total trials

What the Registry Record Tells You About NCT02620748

The ClinicalTrials.gov registry entry for NCT02620748 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is George Washington University, which has 133 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Fibroids appearing as the primary indexed condition, and to 2 interventions - of which Tranexamic Acid is the first listed.

NCT02620748 reports 1 study location spanning 1 distinct geographic area - top geographies include District of Columbia.

Frequently Asked Questions

What is clinical trial NCT02620748 about?

NCT02620748 is a clinical study titled "Use of Intravenous Tranexamic Acid During Myomectomy". The purpose of this study is to determine the effect of the early administration of intravenous (IV) Tranexamic acid (TA) on perioperative bleeding (as defined by measured intraoperative estimated blood loss (EBL), change in pre and post-operative hemoglobin (Hb), and frequency of blood transfusions...

What is the current status of trial NCT02620748?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2015-03. Estimated completion is 2018-02-22.

What conditions does trial NCT02620748 study?

This clinical trial studies the following conditions: Fibroids, Hemorrhage/Blood Loss During Myomectomies.

What interventions are being tested in trial NCT02620748?

The interventions under investigation include: Tranexamic Acid (DRUG), Saline Solution (OTHER).

Who is sponsoring clinical trial NCT02620748?

This trial is sponsored by George Washington University, which has 133 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02620748 being conducted?

This trial has 1 study location across District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Fibroids

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.